Drug Trial Radar · NCT03631199
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
673
Actual
Start
Dec 21, 2018
Primary completion
Aug 9, 2021
Study completion Jan 26, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 15, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC participants.
Conditions
- Non-small Cell Lung Cancer
Interventions
canakinumabDrug
canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)
canakinumab-matching placeboDrug
canakinumab placebo every 3 weeks (squamous and non-squamous)
pembrolizumabDrug
200 mg every 3 weeks (squamous and non-squamous)
carboplatinDrug
Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)
cisplatinDrug
75 mg/m\^2 every 3 weeks (non-squamous)
paclitaxelDrug
200 mg/m\^2 every 3 weeks (squamous)
nab-paclitaxelDrug
100 mg/m\^2 on Days 1, 8, and 15 of every cycle (squamous)
pemetrexedDrug
500 mg/m\^2 every 3 weeks (non-squamous)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (Safety Run-in): Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: During the first 42 days of dosing
- Part 2 (Double-blind, Randomized, Placebo-controlled): Progression-free Survival (PFS) Per Investigator Assessment Using RECIST v1.1Time frame: 18 months
- Part 2 (Double-blind, Randomized, Placebo-controlled): Overall Survival (OS) Per Investigator Assessment Using RECIST v1.1Time frame: Up to approximately 32 months
Locations
152 sites in 41 countries. Site status is shown where the registry gives one.
Pacific Shores Medical Group
Long Beach, California
USC Kenneth Norris Comprehensive Cancer Center
Los Angeles, California
AdventHealth
Orlando, Florida
Dana Farber Cancer Institute
Boston, Massachusetts
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Wooloongabba, Queensland, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Murdoch, Western Australia, Australia
Novartis Investigative Site
Salzburg, Austria
Novartis Investigative Site
Linz, Upper Austria, Austria
Novartis Investigative Site
Barretos, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Brampton, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Santiago, Chile
Novartis Investigative Site
Temuco, Araucania, Chile
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Harbin, Heilongjiang, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Changsha, Hunan, China
Novartis Investigative Site
Changchun, Jilin, China
Novartis Investigative Site
Xi’an, Shanxi, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Valledupar, Cesar Department, Colombia
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Ostrava, Vitkovice, Czechia
Novartis Investigative Site
Herning, Denmark
Novartis Investigative Site
Oulu, Finland
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Marseille, Bouches Du Rhone, France
Showing 40 of 152 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.